February 5, 2018
The Chase Group is excited to announce our newest partnership and search engagement with Genmab, an international biotechnology company. Genmab is known for a strong foundation in science, specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. To assist with their expansion into full product development, The Chase Group has been retained to recruit a new Head of Bioinformatics, as well as a Director of Drug Safety Operations. To learn more about these exciting opportunities, contact Ken Allison at ken@chasegroup.com.
